MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.amjcard.2013.04.049

Медицинская библиотека · The American journal of cardiology · 2013

Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients.

Deftereos Spyridon, Giannopoulos Georgios, Kossyvakis Charalampos, Efremidis Michael, Panagopoulou Vasiliki, Raisakis Konstantinos, Kaoukis Andreas, Karageorgiou Sofia, Bouras Georgios, Katsivas Apostolos, Pyrgakis Vlasios, Stefanadis Christodoulos

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

There is substantial evidence that the autonomic system plays an important part in the pathogenesis of atrial fibrillation (AF). It appears that, although some patients have a preponderantly sympathetic or vagal overactivation leading to AF, a combined sympathovagal drive is most commonly responsible for AF triggering. The purpose of this hypothesis-generating study was to test whether moxonidine, a centrally acting sympathoinhibitory agent, on top of optimal antihypertensive treatment, can lead to a decrease in AF burden in hypertensive patients with paroxysmal AF. This was a prospective, double-blind, 1-group, crossover study. Hypertensive patients with paroxysmal AF sequentially received treatment with placebo and moxonidine for two 6-week periods, respectively. The change in AF burden (measured as minutes of AF per day in three 48-hour Holter recordings) between the 2 treatment periods was the primary outcome measure. Fifty-six patients (median age 63.5 years, 35 men) were included. During moxonidine treatment, AF burden was reduced from 28.0 min/day (interquartile range [IQR] 15.0 to 57.8) to 16.5 min/day (IQR 4.0 to 36.3; p <0.01). European Heart Rhythm Association symptom severity class decreased from a median of 2.0 (IQR 1.0 to 2.0) to 1.0 (IQR 1.0 to 2.0; p = 0.01). Systolic blood pressure levels were similar in the 2 treatment periods, whereas diastolic blood pressure was lower (p <0.01) during moxonidine treatment. The most frequent complaint was dry mouth (28.6%). No serious adverse events were recorded. In conclusion, treatment with moxonidine, a centrally acting sympathoinhibitory agent, results in reduction of AF burden and alleviation of AF-related symptoms in hypertensive patients with paroxysmal AF.

Для цитирования: Deftereos Spyridon, Giannopoulos Georgios, Kossyvakis Charalampos, Efremidis Michael, Panagopoulou Vasiliki, Raisakis Konstantinos, Kaoukis Andreas, Karageorgiou Sofia, Bouras Georgios, Katsivas Apostolos, Pyrgakis Vlasios, Stefanadis Christodoulos. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients.. The American journal of cardiology. 2013. DOI: 10.1016/j.amjcard.2013.04.049.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.